Celcuity(CELC) - 2023 Q4 - Annual Results

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - Presented nonclinical data demonstrating the superior therapeutic ef ects of gedatolisib compared to other PI3K/AKT/mTOR inhibitors at the 2023 SABCS - Management to host webcast and conference call today, March 27, 2024, at 4:30 p.m. ET "In 2023, we made significant progress advancing development of gedatolisib while strengthening our balance sheet and adding to our leadership team," said Brian Sulliva ...